ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES (ACCORD)

控制糖尿病心血管风险的行动（协议）

• 批准号: 7604192
• 负责人: DAVID J BRILLON
• 金额: $ 1.2万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604192
• 关键词: Cardiovascular Diseases; Cardiovascular system; Cessation of life; Computer Retrieval of Information on Scientific Projects Database; Development; Diabetes Mellitus; Diabetic Retinopathy; Enrollment; Event; Fibrates; Funding; Glycosylated hemoglobin A; Grant; Hyperlipidemia; Hypertension; Individual; Institution; Non-Insulin-Dependent Diabetes Mellitus; Outcome; Participant; Patients; Randomized; Research; Research Personnel; Resources; Source; Standards of Weights and Measures; Stroke; United States National Institutes of Health; cardiovascular risk factor; glycemic control

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. ACCORD is a multi-center study that will enroll 10,000 individuals with type-2 diabetes mellitus and either hypertension or hyperlipidemia who have cardiovascular (CV) disease and/or >2 CV risk factors. Subjects will be randomized to either standard (median HbA1c of 7.5%) or intensive (median HbA1c<6.0%) glycemic control. In addition one 2x2 trial of 5800 participants will evaluate the addition of fibrate therapy to statin therapy. A second 2x2 trial of 4200 patients will evaluate intensive (SBP<120 mmHg) versus conventional (SBP<140mmHg) hypertension therapy. Subjects will be followed for 4-8 years, with the primary outcome being the first occurrence of a major CV event, especially non fatal MI, non fatal stroke or CV death. The development or progression of diabetic retinopathy will also be evaluated

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 ACCORD 是一项多中心研究，将招募 10,000 名患有 2 型糖尿病、患有高血压或高脂血症、患有心血管 (CV) 疾病和/或 > 2 个 CV 危险因素的患者。受试者将被随机分配至标准（中位 HbA1c 为 7.5%）或强化（中位 HbA1c<6.0%）血糖控制组。此外，一项由 5800 名参与者参与的 2x2 试验将评估在他汀类药物治疗中添加贝特类药物治疗。第二项由 4200 名患者参与的 2x2 试验将评估强化（SBP<120 mmHg）与传统（SBP<140mmHg）高血压治疗。受试者将被随访 4-8 年，主要结局是首次发生重大 CV 事件，尤其是非致命性 MI、非致命性中风或 CV 死亡。还将评估糖尿病视网膜病变的发生或进展